<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34723680</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1758-1095</ISSN><JournalIssue CitedMedium="Internet"><Volume>114</Volume><Issue>11</Issue><PubDate><Year>2021</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Journal of the Royal Society of Medicine</Title><ISOAbbreviation>J R Soc Med</ISOAbbreviation></Journal><ArticleTitle>Vaccinating adolescents against SARS-CoV-2 in England: a risk-benefit analysis.</ArticleTitle><Pagination><StartPage>513</StartPage><EndPage>524</EndPage><MedlinePgn>513-524</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/01410768211052589</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To offer a quantitative risk-benefit analysis of two doses of SARS-CoV-2 vaccination among adolescents in England.</AbstractText><AbstractText Label="SETTING">England.</AbstractText><AbstractText Label="DESIGN">Following the risk-benefit analysis methodology carried out by the US Centers for Disease Control, we calculated historical rates of hospital admission, Intensive Care Unit admission and death for ascertained SARS-CoV-2 cases in children aged 12-17 in England. We then used these rates alongside a range of estimates for incidence of long COVID, vaccine efficacy and vaccine-induced myocarditis, to estimate hospital and Intensive Care Unit admissions, deaths and cases of long COVID over a period of 16 weeks under assumptions of high and low case incidence.</AbstractText><AbstractText Label="PARTICIPANTS">All 12-17 year olds with a record of confirmed SARS-CoV-2 infection in England between 1 July 2020 and 31 March 2021 using national linked electronic health records, accessed through the British Heart Foundation Data Science Centre.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Hospitalisations, Intensive Care Unit admissions, deaths and cases of long COVID averted by vaccinating all 12-17 year olds in England over a 16-week period under different estimates of future case incidence.</AbstractText><AbstractText Label="RESULTS">At high future case incidence of 1000/100,000 population/week over 16 weeks, vaccination could avert 4430 hospital admissions and 36 deaths over 16 weeks. At the low incidence of 50/100,000/week, vaccination could avert 70 hospital admissions and two deaths over 16 weeks. The benefit of vaccination in terms of hospitalisations in adolescents outweighs risks unless case rates are sustainably very low (below 30/100,000 teenagers/week). Benefit of vaccination exists at any case rate for the outcomes of death and long COVID, since neither have been associated with vaccination to date.</AbstractText><AbstractText Label="CONCLUSIONS">Given the current (as at 15 September 2021) high case rates (680/100,000 population/week in 10-19 year olds) in England, our findings support vaccination of adolescents against SARS-CoV2.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gurdasani</LastName><ForeName>Deepti</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Queen Mary University of London, London E1 4NS, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhatt</LastName><ForeName>Samir</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Imperial College London, London SW7 2BX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costello</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denaxas</LastName><ForeName>Spiros</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flaxman</LastName><ForeName>Seth</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Imperial College London, London SW7 2BX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenhalgh</LastName><ForeName>Trisha</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University of Oxford, Oxford OX1 2JD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffin</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Leeds, Leeds LS2 9JT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyde</LastName><ForeName>Zo&#xeb;</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0002-5985-1729</Identifier><AffiliationInfo><Affiliation>University of Western Australia, Crawley WA 6009, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katzourakis</LastName><ForeName>Aris</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Oxford, Oxford OX1 2JD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKee</LastName><ForeName>Martin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0121-9683</Identifier><AffiliationInfo><Affiliation>London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michie</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratmann</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Imperial College London, London SW7 2BX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reicher</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of St. Andrews, St. Andrews KY16 9AJ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scally</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>University of Bristol, Bristol BS8 1TH, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomlinson</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0903-5395</Identifier><AffiliationInfo><Affiliation>University College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yates</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Bath, Bath BA2 7AY, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziauddeen</LastName><ForeName>Hisham</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>University of Cambridge, Cambridge CB2 1TN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagel</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University College London, London WC1E 6BT, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/K006584/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/V038109/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S003711/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R015600/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/S003711/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MC_PC_19012</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J R Soc Med</MedlineTA><NlmUniqueID>7802879</NlmUniqueID><ISSNLinking>0141-0768</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067697" MajorTopicYN="N">Adolescent Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067576" MajorTopicYN="N">Child Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N" Type="Geographic">England</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="Y">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="N">Myocarditis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011634" MajorTopicYN="Y">Public Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="Y">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="Y">Vaccination</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical</Keyword><Keyword MajorTopicYN="N">evidence-based practice</Keyword><Keyword MajorTopicYN="N">non-clinical</Keyword><Keyword MajorTopicYN="N">paediatrics</Keyword><Keyword MajorTopicYN="N">public health</Keyword><Keyword MajorTopicYN="N">vaccination programmes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>1</Day><Hour>16</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34723680</ArticleId><ArticleId IdType="pmc">PMC8649477</ArticleId><ArticleId IdType="doi">10.1177/01410768211052589</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Joint Committee on Vaccination and Immunisation. JCVI statement on COVID-19 vaccination of children and young people aged 12 to 17 years (accessed 3rd October 2021).</Citation></Reference><Reference><Citation>Gov.uk. The Medicines and
Healthcare Products Regulatory Agency concludes positive safety profile for
Pfizer/BioNTech vaccine in 12- to 15-year-olds. 2021.
https://www.gov.uk/government/news/the-mhra-concludes-positive-safety-profile-for-pfizerbiontech-vaccine-in-12-to-15-year-olds
(accessed 3rd October 2021).</Citation></Reference><Reference><Citation>Gov.uk. Independent report: JCVI
statement on COVID-19 vaccination of children and young people aged 12 to 17
years: 4 August 2021.
https://www.gov.uk/government/publications/jcvi-statement-august-2021-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years/jcvi-statement-on-covid-19-vaccination-of-children-and-young-people-aged-12-to-17-years-4-august-2021
(accessed 3rd October 2021).</Citation></Reference><Reference><Citation>Gov.uk. Independent report: JCVI
statement on COVID-19 vaccination of children aged 12 to 15 years: 3
September 2021.
https://www.gov.uk/government/publications/jcvi-statement-september-2021-covid-19-vaccination-of-children-aged-12-to-15-years
(accessed 3rd October 2021).</Citation></Reference><Reference><Citation>Office for National Statistics. Technical article: Updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021.</Citation></Reference><Reference><Citation>Stephenson T, Shafran R, De Stavola B, et&#xa0;al. Long COVID and the mental and physical health of children and young people: national matched cohort study protocol (the CLoCk study). BMJ Open 2021; 11: e052838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8392739</ArticleId><ArticleId IdType="pubmed">34446502</ArticleId></ArticleIdList></Reference><Reference><Citation>Radtke T, Ulyte A, Puhan MA and Kriemler S. Long-term symptoms after SARS-CoV-2 infection in children and adolescents. JAMA 2021; 326: 869&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8283661</ArticleId><ArticleId IdType="pubmed">34264266</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller M, Nguyen V, Navaratnam AM, Shrotri M, Kovar J, Hayward AC, et&#xa0;al. Prevalence of persistent symptoms in children during the COVID-19 pandemic: evidence from a household cohort study in England and Wales. MedRxiv. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9645448</ArticleId><ArticleId IdType="pubmed">36375098</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health, Israel.
A New Survey. See https://www.gov.il/he/departments/news/childrenpostcoronaeffects
(last accessed 28 September 2021).</Citation></Reference><Reference><Citation>Molteni ESC, Canas LS, Bhopal SS, Huges RC and Antonelli M. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc Health 2021; 5: 708&#x2013;718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8443448</ArticleId><ArticleId IdType="pubmed">34358472</ArticleId></ArticleIdList></Reference><Reference><Citation>Gov.uk. Correspondence: key
published inputs to the UK CMOs advice on universal vaccination of children
and young people aged 12 to 15 years against COVID-19.
https://www.gov.uk/government/publications/universal-vaccination-of-children-and-young-people-aged-12-to-15-years-against-covid-19
(Last accessed 3rd October 2021).</Citation></Reference><Reference><Citation>European Medicines Agency. COVID-19 vaccine Spikevax approved for children aged 12 to 17 in EU. 2021.</Citation></Reference><Reference><Citation>Pitchers C. Pfizer&#x2019;s COVID jab is
first in EU to be approved for 12-15 year olds. Euronews
2021.
https://www.euronews.com/2021/05/28/ema-approves-pfizer-jab-for-use-on-12-15-year-olds
(Accessed 3rd October 2021).</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Demographic Characteristics of People Receiving COVID-19 Vaccinations in the United States. USA: Centers for Disease Control and Prevention, 2021.</Citation></Reference><Reference><Citation>Reed J. Covid: which countries are
vaccinating children and why? BBC News. See https://www.bbc.co.uk/news/health-58516207 (2021, last
accessed 28 September 2021).</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. COVID-19 Vaccines for Children and Teens, 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">34009769</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace M and Oliver S. COVID-19 mRNA Vaccines in Adolescents and Young adults: Benefit-risk Discussion. USA: Centers for Disease Control, 2021.</Citation></Reference><Reference><Citation>Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation 2021; 144: 471&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8340726</ArticleId><ArticleId IdType="pubmed">34281357</ArticleId></ArticleIdList></Reference><Reference><Citation>Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the Advisory Committee on Immunization Practices &#x2013; United States, June 2021. MMWR Morb Mortal Wkly Rep 2021; 70: 977&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8312754</ArticleId><ArticleId IdType="pubmed">34237049</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimabukuro T. Advisory Committee on Immunization Practices (ACIP). COVID-19 Vaccine safety updates. 23rd June 2021.</Citation></Reference><Reference><Citation>U.S. Department of Health and Human Services. Statement Following Centers for Disease Control ACIP Meeting from Nation&#x2019;s Leading Doctors, Nurses, Pharmacists and Public Health Leaders on Benefits of Vaccination. 2021.</Citation></Reference><Reference><Citation>Jain SS, Steele JM, Fonseca B, et&#xa0;al. COVID-19 vaccination-associated myocarditis in adolescents. Pediatrics 2021. e2021053427; DOI: 10.1542/peds.2021-053427A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2021-053427A</ArticleId><ArticleId IdType="pubmed">34389692</ArticleId></ArticleIdList></Reference><Reference><Citation>Medicines &amp; Healthcare products Regulatory Agency. Coronavirus vaccine &#x2013; weekly summary of Yellow Card reporting. 30 July 2021.</Citation></Reference><Reference><Citation>Boehmer TK, Kompaniyets L, Lavery AM, Hsu J, Ko JY, Yusuf H, et al. Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data &#x2013; United States, March 2020&#x2013;January 2021. Morbidity Mortality Weekly Rep (MMWR) 2021; 70: 1228&#x2013;1232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8422872</ArticleId><ArticleId IdType="pubmed">34473684</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer ME, Taub IB, Kaelber DC. Risk of myocarditis from COVID-19 infection in people under 20: a population-based analysis. MedRxiv. 2021. DOI: 10.1101/2021.07.23.21260998.</Citation></Reference><Reference><Citation>Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med 2021; 385: 1078&#x2013;1090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8427535</ArticleId><ArticleId IdType="pubmed">34432976</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. Nat Med 2021; 27: 601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray STJ, Abdel-Mannan O, Sa M, et al. Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study. Lancet Child Adolesc Health 2021; 5: 631&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8279959</ArticleId><ArticleId IdType="pubmed">34273304</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud GLS, Alfaro-Almagro F, Arthofer C, Wang C, Lange F, Andersson JLR, et&#xa0;al. Brain imaging before and after COVID-19 in UK Biobank. MedRxiv 2021. doi: 10.1101/2021.06.11.21258690.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.06.11.21258690</ArticleId></ArticleIdList></Reference><Reference><Citation>Public Health England. Weekly national Influenza and COVID-19 surveillance report: week 36 report. 9 September 2021.</Citation></Reference><Reference><Citation>Public Health England.
Hospitalisations by age, England. See https://t.co/UC9VXodKXG?amp=1 (last checked 28 September
2021).</Citation></Reference><Reference><Citation>Public Health England.
COVID-19 Health Inequalities Monitoring for England (CHIME)
tool. See https://analytics.phe.gov.uk/apps/chime/ (last checked 28
September 2021).</Citation></Reference><Reference><Citation>SAGE. Ninety-fifth SAGE meeting on
COVID-19. See https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1017296/S1360_SAGE_95_minutes.pdf
(last checked 28 September 2021).</Citation></Reference><Reference><Citation>Gov.uk. Coronavirus
(COVID-19) in the UK. Cases in England. See https://coronavirus.data.gov.uk/details/cases?areaType=nation&amp;areaName=England
(last checked 28 September 2021).</Citation></Reference><Reference><Citation>Clews ML. Covid &#x2018;surge' likely
when schools return, expert warns. Times Educational
Supplement 2021. August 2021
https://www.tes.com/news/covid-surge-schools-pandemic-vaccine-young-nhs
(Last accessed 3rd October 2021).</Citation></Reference><Reference><Citation>Wood A, Denholm R, Hollings S, et&#xa0;al. Linked electronic health records for research on a nationwide cohort of more than 54 million people in England: data resource. BMJ 2021; 373: n826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8413899</ArticleId><ArticleId IdType="pubmed">33827854</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health Israel. Explanation about the Effectiveness of the Vaccine for Coronavirus in Israel. Israel: Ministry of Health Israel, 2021.</Citation></Reference><Reference><Citation>REACT-1 round 13 final report: exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant in England during May to July 2021. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10763627</ArticleId><ArticleId IdType="pubmed">34726481</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. Coronavirus (COVID-19) latest insights: Vaccines 16 September 2021.</Citation></Reference><Reference><Citation>Public Health Scotland.
Daily Case Trends By Age and Sex. See https://www.opendata.nhs.scot/dataset/covid-19-in-scotland/resource/9393bd66-5012-4f01-9bc5-e7a10accacf4
(last checked 28 September 2021).</Citation></Reference><Reference><Citation>Swann OV, Holden KA, Turtle L, et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study. BMJ 2020; 370: m3249&#x2013;m3249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7488201</ArticleId><ArticleId IdType="pubmed">32960186</ArticleId></ArticleIdList></Reference><Reference><Citation>Penner J, Abdel-Mannan O, Grant K, et al. 6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study. Lancet Child Adolesc Health 2021; 5: 473&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pubmed">34043958</ArticleId></ArticleIdList></Reference><Reference><Citation>Toraih EA, Hussein MH, Elshazli RM, et al. Multisystem inflammatory syndrome in pediatric COVID-19 patients: a meta-analysis. World J Pediatr 2021; 17: 141&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7895741</ArticleId><ArticleId IdType="pubmed">33608839</ArticleId></ArticleIdList></Reference><Reference><Citation>Gov.uk. International Severe Acute
Respiratory and Emerging Infection Consortium: supplementary
Information&#x2009;-&#x2009;comparison of children and young people admitted with
SARS-CoV-2 across the UK in the first and second pandemic waves, 9 September
2021. https://www.gov.uk/government/publications/isaric-supplementary-information-comparison-of-children-and-young-people-admitted-with-sars-cov-2-across-the-uk-in-the-first-and-second-pandemic-wa
(Last accessed 3rd October 2021).</Citation></Reference><Reference><Citation>Public Health England. Risk assessment for SARS-CoV-2 variant Delta: 23 July 2021, 2021.</Citation></Reference><Reference><Citation>Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefings, 15&#x2013;17 2021.</Citation></Reference><Reference><Citation>Delahoy MJ, Ujamaa D, Whitaker M, O&#x2019;Halloran A, Anglin O, Burne E, et al. Hospitalizations associated with COVID-19 among children and adolescents &#x2013; COVID-NET, 14 States, March 1, 2020&#x2013;August 14, 2021. Morb Mortality Weekly Rep 2021; 70: 1255&#x2013;1260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8437052</ArticleId><ArticleId IdType="pubmed">34499627</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med 2021; 385: 585&#x2013;594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314739</ArticleId><ArticleId IdType="pubmed">34289274</ArticleId></ArticleIdList></Reference><Reference><Citation>Rella SA, Kulikova YA, Dermitzakis ET and Kondrashov FA. Rates of SARS-CoV-2 transmission and vaccination impact the fate of vaccine-resistant strains. Scientific Reports 2021; 11: 15729.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8324827</ArticleId><ArticleId IdType="pubmed">34330988</ArticleId></ArticleIdList></Reference><Reference><Citation>Gog JR, Hill EM, Danon L and Thompson RN. Vaccine escape in a heterogeneous population: insights for SARS-CoV-2 from a simple model. The Royal Society. See 10.1098/rsos.210530 (last checked 28 September 2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsos.210530</ArticleId><ArticleId IdType="pmc">PMC8278051</ArticleId><ArticleId IdType="pubmed">34277027</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillis SD, Unwin HJT, Chen Y, et al. Global minimum estimates of children affected by COVID-19-associated orphanhood and deaths of caregivers: a modelling study. Lancet 2021; 398: 391&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8293949</ArticleId><ArticleId IdType="pubmed">34298000</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. London: Office for National Statistics, 2021.</Citation></Reference><Reference><Citation>Gurdasani D, Alwan NA, Greenhalgh T, et&#xa0;al. School reopening without robust COVID-19 mitigation risks accelerating the pandemic. Lancet 2021; 397: 1177&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9755467</ArticleId><ArticleId IdType="pubmed">33713595</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Interim Public Health Recommendations for Fully Vaccinated People. USA: Centers for Disease Control, 2021.</Citation></Reference><Reference><Citation>World Health Organisation. COVID-19 Virtual Press conference transcript&#x2009;-&#x2009;25 June 2021. Geneva: WHO, 2021.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>